MEF2A sequence variants in Turkish population

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 4, 2008, Pages 465-467

  Gulec, Sukru ^a   Ruchan Akar, Ahmet ^a,b   Akar, Nejat ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

MEF2A; Myocardial infarction

Indexed keywords

GENE PRODUCT; MYOCYTE ENHANCER FACTOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE; GENE DELETION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; INTRON; MYOCYTE ENHANCER FACTOR 2 GENE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TURKEY (REPUBLIC);

ADULT; AGED; HUMANS; MADS DOMAIN PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOGENIC REGULATORY FACTORS; POLYMORPHISM, GENETIC; TURKEY;

EID: 51849093638     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607306403     Document Type: Article

References (18)

1. Olson EN Coronary artery disease and the MEF2A transcription factor. Sci Aging Knowledge Environ. 2003 ; 48: 33.
2. Yusuf S. Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study. Eur Heart J. 2001 ; 22: 103-104.
3. Bhagavatula MR, Fan C., Shen GQ, et al. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet. 2004 ; 13: 3181-3188.
4. Wang L., Fan C., Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003 ; 302: 1578-1581.
5. Hobson, GM, Krahe R., Garcia E., Siciliano MJ, Funanage VL Regional chromosomal assignments for four members of the MADS domain transcription enhancer factor 2 (MEF2) gene family to human chromosomes 15q26, 19p12, 5q14, and 1q12-q23. Genomics. 1995 ; 29: 704-711.
6. Firulli AB, Miano JM, Bi W., et al. Myocyte enhancer binding factor-2 expression and activity in vascular smooth muscle cells. Association with the activated phenotype. Circ Res. 1996 ; 78: 196-204.
7. Breitbart RE, Liang CS, Smoot LB, Laheru DA, Mahdavi V., Nadal-Ginard B. A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage. Development. 1993 ; 118: 1095-1106.
8. Borghi S., Molinari S., Razzini G., Parise F., Battini R., Ferrari S. The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. J Cell Sci. 2001 ; 114: 4477-4483.
9. Yu YT Distinct domains of myocyte enhancer binding factor-2A determining nuclear localization and cell type-specific transcriptional activity. J Biol Chem. 1996 ; 271: 24675-24683.
10. Han J., Jiang Y., Li Z., Kravchenko VV, Ulevitch RJ Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature. 1997 ; 386: 296-299.
11. Kato Y., Kravchenko VV, Tapping RI, Han J., Ulevitch RJ, Lee JD BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 1997 ; 16: 7054-7066.
12. Ornatsky OI, Cox DM, Tangirala P., et al. Post-translational control of the MEF2A transcriptional regulatory protein. Nucleic Acids Res. 1999 ; 27: 2646-2654.
13. González P., García-Castro M., Reguero JR, et al. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J Med Genet. 2006 ; 43: 167-169.
14. Weng L., Kavaslar N., Ustaszewska A., et al. Lack of MEF2A mutations in coronary artery disease. J Clin Invest. 2005 ; 115: 1016-1020.
15. Olson EN Undermining the endothelium by ablation of MAPK-MEF2 signaling. J Clin Invest. 2004 ; 113: 1110-1112.
16. Visvikis-Siest S., Marteau JB Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol. 2006 ; 17: 139-151.
17. Horan, PG, Allen AR, Hughes AE, et al. Lack of MEF2A Delta7aa mutation in Irish families with early onset ischaemic heart disease, a family based study. BMC Med Genet. 2006 ; 7: 65.
18. Kajimoto, K., Shioji K., Tago N., et al. Assessment of MEF2A mutations in myocardial infarction in Japanese patients. Circ J. 2005 ; 69: 1192-1195.